As evidence, he points to the acquisition of neurological therapy business Reata Pharmaceuticals by Biogen for $US7.3 billion ($11.2 billion) in July 2023.By comparison, Neuren had a market value of $2.9 billion on February 12 and De Silva says Reata’s lead drug, Skyclarys, treats a condition two-and-a-half times less prevalent than Rett syndrome.
Daybue is exceeding forecasts for initial adoption and patients are tolerating the treatment regimen above expectations,” says Smith. “More excitingly, the next drug [at the clinical trial stage] has produced positive topline results with the phase 2 trial.”Hashan De Silva, founder and managing partner at medtech investment fund KP Rx, reckons Neuren’s success makes it a takeover target for big pharma. De Silva formerly worked as a healthcare analyst at broker CLSA and hedge fund Karst Peak.
Neuren: Sophie Smith, an investment analyst for the SGH Medical Technology Fund, believes the biotech company will continue its stunning rise – 1609 per cent higher over the past five years. Neuren has commercialised a drug named Daybue to treat neurological disorder Rett syndrome in children and has other drugs in clinical trials.
- Forums
- ASX - By Stock
- Merck to acquire Prometheus in a US$ 10.8 b deal
As evidence, he points to the acquisition of neurological...
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.72 |
Change
-0.150(0.72%) |
Mkt cap ! $2.648B |
Open | High | Low | Value | Volume |
$20.96 | $21.28 | $20.61 | $4.984M | 239.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 782 | $20.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.72 | 1021 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 782 | 20.610 |
2 | 3495 | 20.600 |
2 | 649 | 20.590 |
2 | 1774 | 20.570 |
1 | 145 | 20.550 |
Price($) | Vol. | No. |
---|---|---|
20.720 | 1021 | 2 |
20.730 | 5256 | 1 |
20.750 | 2517 | 1 |
20.790 | 782 | 1 |
20.800 | 649 | 2 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online